ResearcherOspedale G.B. Morgagni - L.PierantoniActive in the last 2 years
Cecilia Binda
Matched on ORCID iD 0000-0003-1148-9684; OpenAlex author ID A5018960368. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 26
2022: 2 papers · 2023: 1 paper · 2024: none · 2025: none · 2026: 2 papers
Papers 5
- Discovering Hereditary Risk Through Surveillance: A Prospective Genetic Analysis of Individuals With Familial Pancreatic Cancer. Co-author DOI 10.1002/ueg2.70187↗
- Rim enhancement on imaging of pancreatic ductal adenocarcinoma: systematic review and meta-analysis of biological and prognostic values. Co-author DOI 10.1007/s11547-025-02131-7↗
- Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.01.016↗
- Trial sequential analysis of randomized controlled trials on neoadjuvant therapy for resectable pancreatic cancer. Co-author DOI 10.1016/j.ejso.2022.04.011↗
- Microbiota in the Natural History of Pancreatic Cancer: From Predisposition to Therapy. Co-author DOI 10.3390/cancers15010001↗
Closest collaborators
The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Alessandro Cucchetti · 3 shared papers, 2022–2026 · strength 0.64
- Paper Rim enhancement on imaging of pancreatic ductal adenocarcinoma: systematic review and meta-analysis of biological and p… DOI 10.1007/s11547-025-02131-7↗
- Paper Trial sequential analysis of randomized controlled trials on neoadjuvant therapy for resectable pancreatic cancer. DOI 10.1016/j.ejso.2022.04.011↗
- Paper Microbiota in the Natural History of Pancreatic Cancer: From Predisposition to Therapy. DOI 10.3390/cancers15010001↗
- Giorgio Ercolani · 3 shared papers, 2022–2026 · strength 0.64
- Paper Rim enhancement on imaging of pancreatic ductal adenocarcinoma: systematic review and meta-analysis of biological and p… DOI 10.1007/s11547-025-02131-7↗
- Paper Trial sequential analysis of randomized controlled trials on neoadjuvant therapy for resectable pancreatic cancer. DOI 10.1016/j.ejso.2022.04.011↗
- Paper Microbiota in the Natural History of Pancreatic Cancer: From Predisposition to Therapy. DOI 10.3390/cancers15010001↗
- Massimo Falconi · 2 shared papers, 2022–2026 · strength 0.37
- Paper Discovering Hereditary Risk Through Surveillance: A Prospective Genetic Analysis of Individuals With Familial Pancreati… DOI 10.1002/ueg2.70187↗
- Paper Trial sequential analysis of randomized controlled trials on neoadjuvant therapy for resectable pancreatic cancer. DOI 10.1016/j.ejso.2022.04.011↗
- Carlo Fabbri · 2 shared papers, 2022 · strength 0.32
- Matteo Renzulli · 1 shared paper, 2026 · strength 0.32
- Emanuela Giampalma · 1 shared paper, 2026 · strength 0.32
- Matteo De Pastena · 1 shared paper, 2026 · strength 0.20
- Giuseppe Malleo · 1 shared paper, 2026 · strength 0.20
- Erica Secchettin · 1 shared paper, 2026 · strength 0.20
- Marta Puzzono · 1 shared paper, 2026 · strength 0.20
- Giuliana Sereni · 1 shared paper, 2026 · strength 0.20
- Arianna Dal Buono · 1 shared paper, 2026 · strength 0.20
- Alessandro Zerbi · 1 shared paper, 2026 · strength 0.20
- Raffaele De Luca · 1 shared paper, 2026 · strength 0.20
- Giulia Martina Cavestro · 1 shared paper, 2026 · strength 0.20
- Gaetano Lauri · 1 shared paper, 2026 · strength 0.20
- Lívia Archibugi · 1 shared paper, 2026 · strength 0.20
- Francesco DE COBELLI · 1 shared paper, 2026 · strength 0.20
- Luigi Laghi · 1 shared paper, 2026 · strength 0.20
- Gabriella Lionetto · 1 shared paper, 2026 · strength 0.20
- Carrara Silvia · 1 shared paper, 2026 · strength 0.20
- Gabriele Capurso · 1 shared paper, 2026 · strength 0.20
- Paolo Giorgio Arcidiacono · 1 shared paper, 2026 · strength 0.20
- Salvatore Paiella · 1 shared paper, 2026 · strength 0.20
- Roberto Salvia · 1 shared paper, 2026 · strength 0.20
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.